Anixa Biosciences Zukünftiges Wachstum
Future Kriterienprüfungen 0/6
Anixa Biosciences's earnings are forecast to decline at 16% per annum. Der Gewinn pro Aktie wird voraussichtlich sinken um 11.7% pro Jahr.
Wichtige Informationen
-16.0%
Wachstumsrate der Gewinne
-11.7%
EPS-Wachstumsrate
Biotechs Gewinnwachstum | 24.4% |
Wachstumsrate der Einnahmen | n/a |
Zukünftige Eigenkapitalrendite | n/a |
Analystenabdeckung | Low |
Zuletzt aktualisiert | 10 Jun 2024 |
Jüngste Aktualisierungen zum künftigen Wachstum
Recent updates
We're Hopeful That Anixa Biosciences (NASDAQ:ANIX) Will Use Its Cash Wisely
May 23We're Not Worried About Anixa Biosciences' (NASDAQ:ANIX) Cash Burn
Jan 19We Think Anixa Biosciences (NASDAQ:ANIX) Can Easily Afford To Drive Business Growth
Oct 06Is There An Opportunity With Anixa Biosciences, Inc.'s (NASDAQ:ANIX) 41% Undervaluation?
Apr 27Are Investors Undervaluing Anixa Biosciences, Inc. (NASDAQ:ANIX) By 36%?
Jan 13We're Interested To See How Anixa Biosciences (NASDAQ:ANIX) Uses Its Cash Hoard To Grow
Sep 26Anixa adds 11% after dosing initiation in CAR-T ovarian cancer trial
Aug 15Anixa to get additional US patent linked to breast cancer vaccine technology
Jul 21Anixa Biosciences (NASDAQ:ANIX) Is In A Good Position To Deliver On Growth Plans
Jun 13Anixa: Making Sense Of A Bullish Move Up In Bearish Biotech Times
May 11We're Interested To See How Anixa Biosciences (NASDAQ:ANIX) Uses Its Cash Hoard To Grow
Feb 24Companies Like Anixa Biosciences (NASDAQ:ANIX) Can Afford To Invest In Growth
Oct 28Our First Look At Anixa Biosciences
Sep 23Here's Why We're Not At All Concerned With Anixa Biosciences' (NASDAQ:ANIX) Cash Burn Situation
Jun 12OntoChem assigns Anixa covid-19 drug discovery project to MolGenie
May 07Anixa Biosciences (NASDAQ:ANIX) Is In A Good Position To Deliver On Growth Plans
Jan 13Anixa Biosciences, Cleveland Clinic in ovarian cancer vaccine pact
Dec 01Gewinn- und Umsatzwachstumsprognosen
Datum | Umsatz | Gewinne | Freier Cashflow | Bargeld aus operativen Tätigkeiten | Durchschn. Anz. Analysten |
---|---|---|---|---|---|
10/31/2025 | N/A | -15 | N/A | N/A | 1 |
10/31/2024 | N/A | -14 | N/A | N/A | 1 |
4/30/2024 | N/A | -12 | -7 | -7 | N/A |
1/31/2024 | 0 | -11 | -7 | -7 | N/A |
10/31/2023 | 0 | -10 | -6 | -6 | N/A |
7/31/2023 | 0 | -11 | -6 | -6 | N/A |
4/30/2023 | 0 | -11 | -6 | -6 | N/A |
1/31/2023 | N/A | -12 | -7 | -7 | N/A |
10/31/2022 | N/A | -14 | -6 | -6 | N/A |
7/31/2022 | 0 | -14 | -6 | -6 | N/A |
4/30/2022 | 0 | -16 | -6 | -6 | N/A |
1/31/2022 | 0 | -15 | -5 | -5 | N/A |
10/31/2021 | 1 | -13 | -5 | -5 | N/A |
7/31/2021 | 1 | -11 | -5 | -5 | N/A |
4/30/2021 | 1 | -9 | -5 | -5 | N/A |
1/31/2021 | 1 | -10 | -5 | -5 | N/A |
10/31/2020 | N/A | -10 | -6 | -6 | N/A |
7/31/2020 | N/A | -10 | -6 | -6 | N/A |
4/30/2020 | N/A | -9 | -5 | -5 | N/A |
1/31/2020 | 0 | -9 | -6 | -5 | N/A |
10/31/2019 | 0 | -12 | -5 | -5 | N/A |
7/31/2019 | 0 | -15 | -5 | -4 | N/A |
4/30/2019 | 1 | -18 | -5 | -5 | N/A |
1/31/2019 | 1 | -17 | -4 | -4 | N/A |
10/31/2018 | 1 | -14 | -4 | -4 | N/A |
7/31/2018 | 1 | -10 | -4 | -4 | N/A |
4/30/2018 | 1 | -7 | -4 | -4 | N/A |
1/31/2018 | 0 | -5 | N/A | -4 | N/A |
10/31/2017 | 0 | -7 | N/A | -4 | N/A |
7/31/2017 | 1 | -6 | N/A | -4 | N/A |
4/30/2017 | 0 | -6 | N/A | -3 | N/A |
1/31/2017 | 0 | -7 | N/A | -4 | N/A |
10/31/2016 | 0 | -5 | N/A | -3 | N/A |
7/31/2016 | 0 | -5 | N/A | -4 | N/A |
4/30/2016 | 0 | -6 | N/A | -3 | N/A |
1/31/2016 | 0 | -7 | N/A | -4 | N/A |
10/31/2015 | 0 | -1 | N/A | 1 | N/A |
7/31/2015 | 2 | -3 | N/A | 2 | N/A |
4/30/2015 | 3 | -1 | N/A | 2 | N/A |
1/31/2015 | 4 | -2 | N/A | 3 | N/A |
10/31/2014 | 4 | -10 | N/A | -2 | N/A |
7/31/2014 | 3 | -9 | N/A | -3 | N/A |
4/30/2014 | 1 | -12 | N/A | -3 | N/A |
1/31/2014 | 0 | -12 | N/A | -3 | N/A |
10/31/2013 | 0 | -10 | N/A | -3 | N/A |
7/31/2013 | 0 | -9 | N/A | -4 | N/A |
Analystenprognosen zum zukünftigen Wachstum
Einkommen vs. Sparrate: ANIX wird in den nächsten 3 Jahren voraussichtlich unrentabel bleiben.
Ertrag vs. Markt: ANIX wird in den nächsten 3 Jahren voraussichtlich unrentabel bleiben.
Hohe Wachstumserträge: ANIX wird in den nächsten 3 Jahren voraussichtlich unrentabel bleiben.
Einnahmen vs. Markt: Die Daten reichen nicht aus, um festzustellen, ob die Einnahmen von ANIX schneller wachsen werden als der Markt von US.
Hohe Wachstumseinnahmen: ANIX wird im nächsten Jahr voraussichtlich keine Einnahmen haben.
Wachstumsprognosen für den Gewinn je Aktie
Künftige Eigenkapitalrendite
Künftige Eigenkapitalrendite: Unzureichende Daten, um festzustellen, ob die Eigenkapitalrendite von ANIX in 3 Jahren voraussichtlich hoch sein wird